Literature DB >> 17129183

Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches.

Richard Schulz1.   

Abstract

A new paradigm of matrix metalloproteinase-2 (MMP-2) action in the heart undergoing oxidative stress has emerged. Although best known for its role in the proteolysis of extracellular protein targets, MMP-2 is also localized to the sarcomere within the cardiomyocyte. Oxidative stress activates full-length MMP-2 without need for proteolytic processing and inactivates an endogenous inhibitor, tissue inhibitor of metalloproteinase-4. MMP-2 proteolyzes specific targets within the cell to cause acute, reversible contractile dysfunction. Inhibitors of MMPs are discussed and their possible use for the therapy of acute heart injury caused by oxidative stress is examined.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17129183     DOI: 10.1146/annurev.pharmtox.47.120505.105230

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  85 in total

Review 1.  Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility.

Authors:  György Dormán; Sándor Cseh; István Hajdú; László Barna; Dénes Kónya; Krisztina Kupai; László Kovács; Péter Ferdinandy
Journal:  Drugs       Date:  2010-05-28       Impact factor: 9.546

Review 2.  Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?

Authors:  Santiago Rivera; Michel Khrestchatisky; Leszek Kaczmarek; Gary A Rosenberg; Diane M Jaworski
Journal:  J Neurosci       Date:  2010-11-17       Impact factor: 6.167

Review 3.  Extracellular Matrix in Ischemic Heart Disease, Part 4/4: JACC Focus Seminar.

Authors:  Nikolaos G Frangogiannis; Jason C Kovacic
Journal:  J Am Coll Cardiol       Date:  2020-05-05       Impact factor: 24.094

4.  Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension.

Authors:  C S Ceron; M M Castro; E Rizzi; M F Montenegro; V Fontana; M C O Salgado; R F Gerlach; J E Tanus-Santos
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

5.  Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury.

Authors:  Mohammad A M Ali; Woo Jung Cho; Bryan Hudson; Zamaneh Kassiri; Henk Granzier; Richard Schulz
Journal:  Circulation       Date:  2010-11-01       Impact factor: 29.690

6.  Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis.

Authors:  Pallavi Garg; Matam Vijay-Kumar; Lixin Wang; Andrew T Gewirtz; Didier Merlin; Shanthi V Sitaraman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-02       Impact factor: 4.052

7.  Role of Tetra Amino Acid Motif Properties on the Function of Protease-Activatable Viral Vectors.

Authors:  T M Robinson; J Judd; M L Ho; J Suh
Journal:  ACS Biomater Sci Eng       Date:  2016-09-28

8.  Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction.

Authors:  Hui-Zhong Zhou; Xiaokui Ma; Mary O Gray; Bo-qing Zhu; Anita P Nguyen; Anthony J Baker; Ursula Simonis; Gary Cecchini; David H Lovett; Joel S Karliner
Journal:  Biochem Biophys Res Commun       Date:  2007-04-23       Impact factor: 3.575

9.  Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia.

Authors:  Karni S Moshal; Srinivas M Tipparaju; Thomas P Vacek; Munish Kumar; Mahavir Singh; Iluiana E Frank; Phani K Patibandla; Neetu Tyagi; Jayesh Rai; Naira Metreveli; Walter E Rodriguez; Michael T Tseng; Suresh C Tyagi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-20       Impact factor: 4.733

10.  Restoration of contractility in hyperhomocysteinemia by cardiac-specific deletion of NMDA-R1.

Authors:  Karni S Moshal; Munish Kumar; Neetu Tyagi; Paras K Mishra; Naira Metreveli; Walter E Rodriguez; Suresh C Tyagi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-01-30       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.